Myotonic dystrophy type 1(DM1), the most common form of adult-onset muscular dystrophy, is caused by an expanded (CTG) n repeat in the 3' untranslated region (UTR) of the DM protein kinase (DMPK) gene. The toxic RNA transcripts produced from the mutant allele alter the function of RNA binding proteins leading to the depletion of muscleblind-like (MBNL) proteins and an increase in steady state levels of CUG-binding protein 1 (CUGBP1). The role of increased CUGBP1 in DM1 pathogenesis is well studied using genetically engineered mouse models. However, the effect of reduction of CUGBP1 is not clear yet. In this study, we generated CUGBP1 knockout mice, which also carry an inducible toxic RNA transgene to test the effects of CUGBP1 reduction in RNA toxicity. We found that while absence of CUGBP1 did not correct splicing defects, it did however mitigate the increase in translational targets of CUGBP1 (MEF2A and CEBPβ). Notably, we found that loss of CUGBP1 prevented deterioration of muscle function by the toxic RNA, and resulted in better muscle histopathology. These data suggest reduction of CUGBP1 may be beneficial to the muscular dystrophy associated with RNA toxicity.
Introduction
Myotonic dystrophy type 1 (DM1) is the most common cause of the adult-onset muscular dystrophy with an incidence of 1 in 8000 and is a multi-systemic disorder (1) . Major features of this autosomal dominant disorder are myotonia, muscle weakness, atrophy, smooth muscle dysfunction, cardiac defects and insulin resistance (2) . DM1 is triggered by the expanded (CTG) n triple repeat in the 3'-untranslated region (UTR) of the DMPK gene (1) . This is transcribed to produce mutant RNAs containing CUG repeats that are retained in the nucleus to form RNA foci (3, 4) . This affects the nuclear and cytoplasmic activities of RNA binding proteins such as muscleblind-like 1 (MBNL1) and CUG-binding protein 1 (CUGBP1) (5) (6) (7) (8) .
MBNL1 binds to the expanded CUG repeat and co-localizes with the RNA foci, causing a local reduction of MBNL1 (6, 7) . Consequently, the activity of MBNL1 as a splicing regulator is impaired, resulting in aberrant alternative splicing of target genes (9) . Consistent with the loss of MBNL1 function, an analysis of MBNL1 knockout mice (Mbnl E3/E3 ) showed that these mice developed some of the characteristic features of DM1, including misregulated mRNA splicing, muscle histopathological changes, cataracts, and myotonia (10) . Moreover, an adenoviral delivery of MBNL1 reversed the splicing changes and myotonia, again underscoring the importance of MBNL1 in the DM1 disease phenotype (11) .
In addition to MBNL1, CUGBP1, a member of CUG-BP and ETR-3-like factor (CELF) family, is implicated in the disease process. CUGBP1 has been reported to have multiple functions in RNA metabolism including regulation of alternative splicing, RNA stability and translational regulation of its RNA targets (12) (13) (14) (15) (16) . The mutant DMPK transcript is thought to activate PKC activity, leading to a hyperphosphorylation of CUGBP1 (17) , resulting in the stabilization of and increased steady state levels of CUGBP1 in DM1 skeletal muscle and heart tissues. Transgenic mice over-expressing CUGBP1
showed neonatal lethality, skeletal muscle histological changes, and misregulated splicing pattern observed in DM1 patients (18, 19) . Heart specific over-expression of CUGBP1 caused premature lethality, histopathological and echocardiographic abnormalities, and splicing defects (20) . Two different transgenic mouse models which over-expressed CUGBP1 in skeletal muscle developed DM1 features.
One mouse model showed that CUGBP1 responsive alternative splicing events were misregulated in skeletal muscle and that CUGBP1 affects muscle integrity and function (21) . In the other model, muscular dystrophy, fiber type switching, and delayed muscle development were seen in conjunction with increased levels of p21 and MEF2A (both of which are translational targets of CUGBP1) (18) . Both of these models exhibited muscle loss, impaired muscle function and dystrophic muscle histology. These data demonstrate that increased CUGBP1 contributes to DM1 pathogenesis and suggests that reduction of CUGBP1 in a DM1 mouse model may have beneficial effects.
To test this, we generated CUGBP1 knockout mice that also carried an inducible toxic RNA transgene (5-313) (22) . We found muscle function in these double transgenic mice was protected and the histopathological features were milder as compared to mice carrying only the toxic RNA transgene, despite the fact that many alternative splicing events known to be mis-regulated in DM1 were not corrected by the absence of CUGBP1. This was associated with decreased Nkx2-5 levels in skeletal muscle from Cugbp1 -/-mice expressing the toxic RNA, and corresponded to the milder histopathology of the muscle in these mice. Additionally, the protein levels of MEF2A and C/EBP were reduced in the absence of CUGBP1. These data suggest reduction of CUGBP1 may be beneficial to the muscular dystrophy associated with DM1.
Results

Levels of CUGBP1 correlate with skeletal muscle histopathology in DM1.
We first evaluated CUGBP1 levels in skeletal muscles from patients with DM1. Western blot analyses of muscle extracts showed increased CUGBP1 (up to 5 fold) that correlated well with muscle histopathology (Fig. 1A) . Next, we investigated CUGBP1 in a doxycycline inducible RNA toxicity mouse model of DM1 (5-313), which expresses an eGFP gene fused to the DMPK 3'UTR (CTG) 5 (22) . CUGBP1 was increased by induction of toxic RNA (between 1.5 to 5 fold) and the expression was highest in the muscles with the most severe histopathology (Fig. 1B) . Thus the mouse model accurately represented these aspects of the disease phenotype providing a basis for further investigations.
Absence of CUGBP1 does not affect MBNL1 or CUGBP2 in mice with RNA toxicity.
To determine whether reduction of CUGBP1 will improve the muscle pathology, /5-313 mice even after induction (Fig. 2) .
Induction of the transgene was confirmed by qRT-PCR (Supp. Fig. S2B ) and western blot for eGFP ( Fig.   2 ).
We tested whether any of the other CELF proteins compensated for the absence of CUGBP1. The level of Cugbp2 expression was determined using qRT-PCR (Supp. Fig. S2C ) and western blot (Fig. 2 ). Both
Cugbp2 mRNA and protein levels of CUGBP2 were unaffected by the absence of CUGBP1 and the presence of toxic RNA. We also performed qRT-PCR to quantify the levels of Celf4 expression and found it was not expressed in skeletal muscle (data not shown). MBNL1 protein levels were assayed by western blot. Neither RNA toxicity nor the absence of CUGBP1 changed the levels of total MBNL1
protein in this mouse model (Fig. 2) . (Fig. 3A, B) . Thus unlike the RNA toxicity mice expressing CUGBP1 where we observed a significant decrease in function, the loss of CUGBP1 resulted in a preservation of muscle function in the 5-313 +/-transgenic mice with RNA toxicity.
Absence of CUGBP1 preserves muscle function in the presence of RNA toxicity
We also examined cardiac function by ECG and myotonia using EMG. Both Cugbp1 +/+ and Cugbp1
-/-mice developed prolonged PR intervals on the ECG and myotonia by two weeks after induction. (Supp. Table S1 ). Absence of CUGBP1 did not improve the cardiac conduction defects or myotonia, in the induced Cugbp1 -/-/5-313 +/-mice.
Absence of CUGBP1 does not correct misregulated alternative splicing.
Misregulation of developmental alternative splicing transitions is a characteristic molecular feature of DM1, and CUGBP1 is known to play an important role in alternative splicing (6, 19, (24) (25) (26) . Some of the splicing targets are antagonistically regulated by MBNL1 and CUGBP1 while others are specific to MBNL1 or CUGBP1 (13, 27) . To determine whether the removal of CUGBP1 restores the missplicing events affected by the toxic RNA, we analyzed various splicing targets which are abnormally spliced in the 5-313 +/+ model. Aberrant splicing of Clcn-1 exon 7 is a key feature of DM1 and responsible for myotonia (28, 29) . Both Cubgp1 +/+ and -/-mice showed misregulation of Clcn-1 splicing in the presence of toxic RNA (Fig. 4A ). Additionally Tnnt3 exon F (the fetal isoform) and Smyd1 exon 39 were misregulated in skeletal muscle from both induced +/+ and -/-mice (24, 30, 31) (Fig. 4A ). Splicing targets reported to be CUGBP1 specific (Nrap exon 12 and Fxr1h exon 15, 16) were also examined and found to be misregulated by toxic RNA in both the +/+ and -/-mice (13, 21, (32) (33) (34) (Fig. 4B ). In summary, the alternative splicing events that are misregulated in this RNA toxicity model were not rescued by knockout of CUGBP1.
Interestingly, we found that the absence of CUGBP1 lead to a more embryonic pattern in all splicing events compared with mice expressing CUGBP1, even in the absence of toxic RNA (Fig. 4A, B ).
To determine if the muscle from Cugbp1 -/-mice is in an earlier embryonic/developmental stage, we looked at the expression of embryonic myosin heavy chain (Myh3) by qRT-PCR. Cugbp1 -/-mice have 3.6 fold (P < 0.05) more Myh3 than Cugbp1 +/+ mice in the absence of RNA toxicity and in the absence of any active degeneration/regeneration process ( Fig. 4C ). This is consistent with a more developmentally immature muscle. The levels increased to 6.7 fold after induction of RNA toxicity ( Fig. 4C ), like the responses seen in mice with CUGBP1. These data suggest that CUGBP1 is not as strong a splicing modulator in RNA toxicity, and that other factors affected by toxic RNA (e.g. MBNL1) may have a greater impact on the splicing events.
Absence of CUGBP1 leads to better muscle histology.
Hematoxylin and eosin staining were performed on quadriceps muscles from Cugbp1
Cugbp1
-/-/5-313 mice. These muscles were graded according to a histopathology scoring system we have developed in the lab. Both uninduced Cugbp1 +/+ and -/-mice showed normal muscle histology with peripherally located nuclei and uniform fiber size (Fig. 5A) . Atrophic fibers and inflammation were not observed in these muscles. By 2 weeks on 0.2% dox induction, Cugbp1 +/+ /5-313 +/+ mice had characteristic DM1 histological feature including increased central nuclei, variation in fiber size and nuclear clumping (Fig. 5A) , as described previously (22) . Their resulting average scores fell within the moderate severity range (Fig. 5B) . However, the histology scores of induced Cugbp1 -/-mice fell within the mild range. In these muscles, only 2-3% of the fibers contained central nuclei and these mice had minimal fiber size variation and no nuclear clumping (Fig. 5A ). Nkx2-5 mRNA levels in the induced Cugbp1 +/+ /5-313 mouse muscles were dramatically increased, whereas the levels were undetectable in the absence of RNA toxicity (Fig. 5C ). However, the induced Cugbp1 -/-mice had 5 times less Nkx2-5 expression relative to the induced Cugbp1 +/+ mice (Fig. 5C ).
Downstream targets of Nkx2-5 like Gata4, Nppa and Nppb (31), were assessed by qRT-PCR and their levels were likewise affected (Supp. Fig. S3 ).
Translational targets of CUGBP1 are also affected in skeletal muscle
CUGBP1 functions as a translational regulator for several genes such as MEF2A and the C/EBP. It has been reported that transgenic mice over-expressing CUGBP1 have elevated levels of MEF2A and a delay in myogenesis (18). To examine whether the level of these translational targets are affected by the presence of RNA toxicity and CUGBP1 status, we analyzed the expression of MEF2A and C/EBP by western blotting. We found that CUGBP1 status had no significant effect on the levels of MEF2A in uninduced mice. However, the level of MEF2A increased in the presence of RNA toxicity in mice wildtype for Cugbp1 and this effect was absent in the muscles of Cugbp1 (Fig. 6B, C) .
Notably, the levels of both the LAP and LIP isoforms were not significantly induced in Cugbp1
-/-/5-313 +/+ (dox+) mice as compared to uninduced mice, and were significantly less than 5-313 +/+ (dox+) mice that expressed CUGBP1 (Fig. 6B, C) .
It has been previously reported that glucocortcoid treatment of mice increased C/EBPin skeletal muscle and regulated factors of muscle atrophy, and that knockdown of C/EBP reduced these levels in myoblasts (36) . Given the improved muscle histology and decreased levels of C/EBPin the Cugbp1 
Discussion
Several studies using CUGBP1 transgenic mice support a role for CUGBP1 in DM1 pathogenesis (18) (19) (20) (21) 37) . Transgenic mice over-expressing CUGBP1 reproduced splicing defects observed in individuals with DM1 and cardiac or muscle specific expression also showed histological and functional DM1 features (19) (20) (21) . Recently, a study using a dominant negative CUGBP1 protein showed rescue of splicing defects in a cell culture system and a DM1 mouse model (34) . In addition, transgenic mice over-expressing a His-tagged CUGBP1 had increased mortality and evidence of disrupted myogenesis, a feature found in congenital DM1 (18) .
These studies also supported the notion that the levels of CUGBP1 have a strong correlation with disease severity (18, 21) . Mice with 2-3 fold elevation of His-CUGBP1showed mild histological changes such as increased numbers of central nuclei, whereas higher levels (4-6 fold) leads to fiber type switching, fiber size variation as well (18) . In another study, using and inducible CUGBP1 transgenic mouse model, an 8-fold increase in CUGBP1 led to severe histopathology in 4 weeks, whereas a lower induction of CUGBP1 (2-fold) resulted in very mild muscle pathology (21) . In our mouse model as well as patient tissues, we also see a clear correlation between CUGBP1 levels and muscle pathology (Fig. 1 ). This suggests that reduced levels of CUGBP1 could result in better muscle histology.
As a prelude to performing experiments presented here, we had done a similar series of experiments using Cugbp1 +/-(i.e. heterozygous knockout mice) and found no significant effects on the measured phenotypes or on CUGBP1 levels (data not shown). So, we examined the consequences of CUGBP1 deficiency in RNA toxicity by producing a complete knockout of CUGBP1 in our inducible RNA toxicity model. The absence of CUGBP1 by itself (i.e. Cugbp1 -/-mice) resulted in weak and small mice that had deficits in running on a treadmill and in grip strength assays (Fig. 3) . Also, these mice developed cataracts, a phenotype commonly seen in patients with DM1 (Supp Fig. 1 ). This is unlikely to be related to the pathogenesis of cataracts in DM1 since CUGBP1 levels are elevated in DM1, not diminished or absent.
Notably, absence of CUGBP1 did not lead to myotonia, obvious cardiac conduction defects, or obvious histopathology in skeletal muscles; phenotypes that are all prominent in DM1. However, there was some evidence for muscle immaturity based on RNA splicing patterns that resembled a more embryonic developmental stage and increased expression of embryonic myosin heavy chain isoforms (Fig. 4) . Though the CUGBP1 deficient mice started off weaker, the fact that there was no further diminution in the muscle function tests (treadmill run and grip strength) when RNA toxicity was induced in these mice, unlike the mice that were expressing CUGBP1 (Fig. 3) , showed that CUGBP1 deficiency preserved muscle function despite the effects of RNA toxicity. Additionally, abnormal muscle histology in mice expressing the toxic RNA was restored towards normal, resulting in mice with milder histopathology (Fig.   5 ). Thus absence of CUGBP1 seems to have a clear protective effect against these adverse effects of RNA toxicity. As well, a number of molecular changes caused by RNA toxicity were minimized by the absence of CUGBP1. For instance, it has been previously proposed that the cytoplasmic function of CUGBP1 as a translational regulator could be disrupted by RNA toxicity (18) . In this model, it is posited that CUGBP1 post-transcriptionally regulated various target mRNAs, such that in DM1, increased CUGBP1 in muscle tissue disrupted myogenesis via up-regulation of translational targets such as MEF2A (18) and C/EBP (38) . Indeed, in our RNA toxicity model, we see significant elevation of both MEF2A
and C/EBPβ in skeletal muscle along with an increase in CUGBP1. Of note, we find that in the absence of CUGBP1 in our RNA toxicity mouse model, there is no significant increase in MEF2A and C/EBP and that this correlates with a beneficial effect on the histopathology and muscle function.
Though it is unclear how the effects on these translational targets could be affecting muscular dystrophy in our model, several recent studies have implicated C/EBPβ in myogenesis and muscle wasting. In a recent study it was found that dexamethasone administration to cultured myoblasts led to increased C/EBPβ, upregulated atrogin-1 and MuRF1 and reduced cell size (36) . Treating the myoblasts with a siRNA against C/EBPβ resulted in reductions in C/EBPβ and MuRF1and was associated with preservation of cell size. RNA toxicity in our mouse model increases C/EBP and MuRF1 levels in skeletal muscle and is associated with muscle weakness, atrophy and histopathology. Of note, the absence of CUGBP1 reduced C/EBPβ and MuRF1 and was associated with decreased atrophy and histopathology in our mouse model, analogous to the results from the myoblast study. Furthermore, another group recently reported that C/EBPβ was expressed in satellite cells in skeletal muscle and that increased expression of C/EBPβ inhibited satellite cell and C2C12 myoblast differentiation and that loss of C/EBP in satellite cells promoted muscle differentiation (39) . This may have relevance to DM1 muscle histopathology as it has been reported that satellite cell numbers were increased in muscles from DM1 patients without a concomitant increase in muscle regeneration, suggestive of a block in satellite cell activation or subsequent recruitment into a differentiation program (40). This is also consistent with reports of defects in differentiation and maturation in satellite cells from patients with DM1 (40, 41).
In summary, CUGBP1 up-regulation clearly correlates with severity of muscle pathology in DM1 patients and in our mouse model of RNA toxicity. However, our data suggests that even complete removal of CUGBP1 does not have a significant effect on key phenotypes of DM1 including myotonia, cardiac conduction defects and surprisingly, even several splicing defects. Thus, therapeutic approaches that target only CUGBP1 seem likely to have serious limitations, as Cugbp1 -/-mice are small and weak and key DM1 phenotypes persist even in the absence of CUGBP1. However, reductions in CUGBP1 did have a beneficial effect on muscle histopathology and preservation of muscle function perhaps through alterations in the functions of CUGBP1 as a translational regulator. This suggests that targeting CUGBP1
could have limited therapeutic benefits with respect to the muscular dystrophy in DM1. But it is likely that this would have to be undertaken in a combinatorial approach with compounds that target MBNL1 sequestration, or the toxic RNA, or other novel pathways affected by RNA toxicity in patients with DM1.
Materials and methods
Mouse models.
All animals were used in accordance with protocols approved by the Animal Care and Use Committee (ACUC) at the University of Virginia. DM1 mouse models were generated as previously described (22) .
All progenies were genotyped by PCR. Six weeks old mice were induced with 0.2 % of doxycycline in drinking water. 5-313 +/-mice were used for the running and the grip strength test. The remaining experiments used 5-313 +/+ mice.
Protein isolation and western blot.
Tissues were homogenized in RIPA buffer (50mM Tris-HCl pH 7.4, 150mM NaCl, 1% NP-40, 0.5% Na 
Treadmill assay and grip strength test.
Mice were examined for running endurance on a treadmill (Columbus Instruments, OH). Mice were started for 1 min at 10m/min and then ran at the speed of 15m/min for 2 min. The treadmill accelerated to 29 m/min at a rate of 2m/min/2min. After 17min, the treadmill was then increased to 30 m/min for 13min.
When the mice reached exhaustion (defined as greater than 5 consecutive seconds on the shock grid without attempting to re-engage the treadmill), they were removed from the device. Total time and total distance were recorded for each trial (Supp . Table S2 ).
Grip strength was measured using a digital grip strength meter, which records the maximal strength an animal exerts while trying to resist an opposing pulling force (Columbus Instruments, Columbus, OH).
Forelimb grip strength was measured using a mouse tension bar. The results of five consecutive trials on the same day were averaged for each animal. Testers were blind to genotype.
ECGs and EMGs.
ECG and EMG were measured as described previously (35) . Mice were anesthetized with intraperitonial valium (2.5 mg/kg body weight) and ketamine (100 mg/kg body weight) and kept warm during the entire procedure. EMGs were carried out with a TD-20 MK1 EMG machine from TECA, using subdermal electrodes for stimulation, and grounding. Three lead ECG was performed with a BioAmp/Powerlab from ADInstrument. All protocols were approved by and performed under the auspices of the UVA Institutional Animal Care and Use Committee.
RNA isolation and RT-PCR.
Total RNA was extracted from skeletal muscle tissues using TRIzol reagent (Invitrogen). cDNA was synthesized from 1g RNA using QuantiTech Reverse Transcription Kit (Qiagen) and then subjected to PCR using gene-specific primers. After separation on a 1% agarose gel or 10% acrylamide gel, bands were quantified using Kodak gel imaging and ImageQuant.
Quantitative RT-PCR (qRT-PCR) was performed using the BioRad iCycler and detected with SYBERGreen dye. Primer sequence and PCR conditions are given in Supp. Table S3 . All assays were done in duplicate, and data normalization was accomplished using an endogenous control (Gapdh). The values were subjected to a 2 (-Ct) formula to calculate the fold change between the control and experimental groups.
Histology.
Quadriceps femoris muscles were collected in isopentane and frozen in liquid nitrogen. Tissues were cut at 6m with a cryostat. Hematoxyline and eosin staining was done according to standard procedures and examined under a light microscope.
Statistics
All data are expressed as mean ± standard deviation. Statistical significance was determined using a two- have five fold more MuRF1 mRNA than uninduced mice (n=7) and these levels are reduced to 1.6 fold in
Cugbp1
-/-/5-313(+dox) (n=5). *P < 0.05, **P < 0.01 and ***P < 0.005 (t-test).
